Lexpos News

Yesterday, the House of Commons Health and Social Care Select Committee published its report on the recent inquiry: Workforce: recruitment, training and retention in health and social care. The report included the following recommendation regarding community pharmacy: There is an opportunity to better utilise the pharmacy workforce, and in doing so, to optimise workloads across [...]

The post Pharmacy bodies issue joint reaction to MPs’ report on workforce appeared first on PSNC Website.

Following the launch of the NHS Profile Manager tool which is being rolled out to pharmacies across England, the NHS Profile Manager implementation lead has written a blog about the tool’s development and benefits. Contractors that have not already done so are encouraged to register for NHS Profile Manager using your personal NHSmail address. Once [...]

The post Update on NHS Profile Manager tool appeared first on PSNC Website.

The Department of Health and Social Care (DHSC) has today (22/07/2022) granted the following list of price concessions: Drug Pack size Price concession Celecoxib 200mg capsules 30 £5.97 Clarithromycin 250mg/5ml oral suspension 70 £5.00 Clotrimazole 500mg pessaries 1 £5.20 Cyclizine 50mg/1ml solution for injection ampoules 5 £6.16 Desloratadine 5mg tablets 30 £4.91 Flucloxacillin 500mg capsules [...]

The post July 2022 Price Concessions 2nd Update appeared first on PSNC Website.

PSNC has agreed to take forward a comprehensive new programme of work to address the 21 RSG proposals that were directed at the Committee. Alongside that, the Committee has reaffirmed its commitment to supporting LPCs through the proposed changes for them, and to working together with LPCs on the 10 joint PSNC and LPC proposals. [...]

The post PSNC launches Transforming Pharmacy Representation (TAPR) Programme    appeared first on PSNC Website.

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 15 Issue 12 July 2022) has been published and includes articles on: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure COVID-19 vaccines and medicines: updates for July 2022 [...]

The post MHRA Drug Safety Update July 2022 appeared first on PSNC Website.